Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.42 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | GLB1 | P16278 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 4/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18948555 | 0.95 | GLB1 (0.42) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL10118772 | 0.88 | GBA1 (0.37) | GBA1 | |
| SCHEMBL10141918 | 0.88 | GBA1 (0.33) | GBA1ALDH1A1 | |
| SCHEMBL10118824 | 0.82 | GBA1 (0.30) | GBA1 | |
| SCHEMBL12231923 | 0.82 | GUSB (0.47) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL10154829 | 0.80 | CHRM2 (0.33) | — | |
| SCHEMBL12231806 | 0.78 | GBA1 (0.37) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL10121287 | 0.77 | PIK3CD (0.42) | — | |
| SCHEMBL27284198 | 0.76 | CHRM2 (0.30) | — | |
| SCHEMBL24379939 | 0.75 | ALDH1A1 (0.40) | EBPSIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | GUSB 329/4885EBP 562/4885SIGMAR1 1216/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | GUSB 329/4885EBP 562/4885SIGMAR1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.